BR9707369A - Pharmaceutical formulation and process for treating allergy and inflammation asthma in a patient - Google Patents

Pharmaceutical formulation and process for treating allergy and inflammation asthma in a patient

Info

Publication number
BR9707369A
BR9707369A BR9707369A BR9707369A BR9707369A BR 9707369 A BR9707369 A BR 9707369A BR 9707369 A BR9707369 A BR 9707369A BR 9707369 A BR9707369 A BR 9707369A BR 9707369 A BR9707369 A BR 9707369A
Authority
BR
Brazil
Prior art keywords
patient
pharmaceutical formulation
treating allergy
inflammation asthma
asthma
Prior art date
Application number
BR9707369A
Other languages
Portuguese (pt)
Inventor
Sven-Erik Dahlen
Edward M Scolnick
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608927.1A external-priority patent/GB9608927D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9707369A publication Critical patent/BR9707369A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
BR9707369A 1996-02-08 1997-02-04 Pharmaceutical formulation and process for treating allergy and inflammation asthma in a patient BR9707369A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1132896P 1996-02-08 1996-02-08
GBGB9608927.1A GB9608927D0 (en) 1996-04-29 1996-04-29 Method of treatment and pharmaceutical composition
PCT/US1997/001799 WO1997028797A1 (en) 1996-02-08 1997-02-04 Method of treatment and pharmaceutical composion

Publications (1)

Publication Number Publication Date
BR9707369A true BR9707369A (en) 1999-07-20

Family

ID=26309231

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9707369A BR9707369A (en) 1996-02-08 1997-02-04 Pharmaceutical formulation and process for treating allergy and inflammation asthma in a patient

Country Status (19)

Country Link
EP (1) EP1014972A4 (en)
JP (1) JPH11504044A (en)
KR (1) KR19990082367A (en)
CN (1) CN1210465A (en)
AU (1) AU732671B2 (en)
BG (1) BG102669A (en)
BR (1) BR9707369A (en)
CA (1) CA2245162A1 (en)
CZ (1) CZ248798A3 (en)
EE (1) EE9800234A (en)
IL (1) IL125446A0 (en)
IS (1) IS4805A (en)
NO (1) NO983641D0 (en)
NZ (1) NZ331160A (en)
PL (1) PL328074A1 (en)
SK (1) SK105698A3 (en)
TR (1) TR199801511T2 (en)
WO (1) WO1997028797A1 (en)
YU (1) YU33298A (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
HUP0101369A3 (en) * 1997-12-23 2002-11-28 Schering Corp Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6248308B1 (en) 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ID29137A (en) * 1998-07-27 2001-08-02 Schering Corp HIGH AFINITY LIGANS FOR ORL-1 NOSISEPTIN RECEPTORS
WO2000015226A1 (en) * 1998-09-10 2000-03-23 Schering Corporation Antihistamines for treating non-infective sinusitis or otitis media
WO2000057880A1 (en) * 1999-03-29 2000-10-05 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
DE10007203A1 (en) * 2000-02-17 2001-08-23 Asta Medica Ag Composition for treating allergic and/or vasomotor rhinitis or allergic conjunctivitis by topical or oral administration, contains synergistic combination of non-sedating antihistamine and leukotriene antagonist
AU2002227240A1 (en) * 2000-10-30 2002-05-15 Schering Corporation Treatment and method using loratadine and montelukast
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
WO2004087095A2 (en) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Osmotic controlled release device containing zafirlukast and an h1-antagonist
EP1680084A2 (en) * 2003-10-21 2006-07-19 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
WO2005089748A1 (en) * 2004-03-17 2005-09-29 Pfizer Limited Combination for treating inflammatory diseases
MX2007004976A (en) 2004-10-25 2007-06-14 Schering Corp M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders.
TR200806298A2 (en) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Pharmaceutical formulation
EP2443134A2 (en) 2009-06-16 2012-04-25 Schering Corporation NOVEL [3,2-c]HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES THEREOF
KR101540191B1 (en) * 2014-02-24 2015-07-28 성균관대학교산학협력단 Composition comprising Loratadine for anti-inflammation
TW202042813A (en) * 2019-01-10 2020-12-01 大陸商江陰貝瑞森製藥有限公司 New formulations containing leukotriene receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Also Published As

Publication number Publication date
YU33298A (en) 1999-11-22
KR19990082367A (en) 1999-11-25
IS4805A (en) 1998-07-22
PL328074A1 (en) 1999-01-04
JPH11504044A (en) 1999-04-06
EP1014972A4 (en) 2004-12-08
AU2257997A (en) 1997-08-28
TR199801511T2 (en) 1998-10-21
WO1997028797A1 (en) 1997-08-14
NZ331160A (en) 2000-07-28
CZ248798A3 (en) 1999-01-13
NO983641L (en) 1998-08-07
SK105698A3 (en) 1999-05-07
EP1014972A1 (en) 2000-07-05
EE9800234A (en) 1998-12-15
CA2245162A1 (en) 1997-08-14
IL125446A0 (en) 1999-03-12
BG102669A (en) 1999-04-30
AU732671B2 (en) 2001-04-26
NO983641D0 (en) 1998-08-07
CN1210465A (en) 1999-03-10

Similar Documents

Publication Publication Date Title
BR9707369A (en) Pharmaceutical formulation and process for treating allergy and inflammation asthma in a patient
BR9612228A (en) Apparatus for the treatment of exhaust in machines and method of use
BR9508906A (en) Process and apparatus for executing deferred transactions
BR9501406A (en) Plant packaging set and plant packaging process
PT1003478E (en) AQUOSOL AQUOSOL PREPARATIONS CONTAINING BIOLOGICALLY ACTIVE MACROMOLECULES AND PROCESS FOR THE PREPARATION OF THEIR RESPIRATORS
BR9708953A (en) Process and set for identifying the user of a mobile communications unit in a mobile communications system
BR9702541A (en) Cosmetic and / or dermatological composition use of the composition and process for non-therapeutic cosmetic treatment
BR9503100A (en) Process and apparatus for making tablets
BR9508586A (en) Compounds of the same preparation process use the same process of treating a clinical condition in a mammal and pharmaceutical composition
BR9503033A (en) Absorbent structure; disposable absorbent product and process for preparing absorbent structure
EE03380B1 (en) Pharmaceutical aerosol formulation and process for its preparation
AR027815A1 (en) PHARMACEUTICAL FORMULATION AND METHOD FOR YOUR PRODUCTION
DE69524402D1 (en) MEDICINE DISPENSER AND ITS CONSTRUCTION METHOD
PT1183029E (en) PHARMACEUTICAL PREPARATION CONTAINING THE ACTIVE DIAMORPHINE PRINCIPLE AND ITS USE IN A PROCESS FOR THE TREATMENT OF OPIACEAL DEPENDENCE
BR9702147A (en) Pharmaceutical composition use of a pharmaceutical composition and process for the treatment of pain associated with periodontal scarification and for the preparation of a pharmaceutical composition
BR9707251A (en) Process compounds for their preparation and pharmaceutical compositions
BR9701946A (en) Skin conditioning composition and cosmetic process
BR9504509A (en) Compound process for its preparation and pharmaceutical formulation
BR9505610A (en) Compound pharmaceutical composition process for the preparation of a compound use and method of treating inflammation and pain
BR9709560A (en) Compound pharmaceutical formulation use of a compound in the process for treating a condition where inhibition of thrombin is necessary and for the preparation of a compound
BR9603072A (en) Hair treatment agent and process for its preparation
BR9503101A (en) Process and apparatus for making tablets
BR9708093A (en) Compound compound use formulation and process for treating 5-hydroxytryptamine-mediated disorders and for compound preparation
BR9708607A (en) Compound pharmaceutical composition use of a compound process for treating or reducing the risk of inflammatory disease in a patient and for the preparation of a compound and chemical intermediate
BR9508584A (en) Process for treating an individual for endotoxemia and for relief usable in the treatment of endotoxemia

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]